Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-08-28
Intellia Therapeutics, Inc.
Intellia develops CRISPR gene-editing medicines led by lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Clinical Option to Rare-Disease Franchise
The five-year case depends less on blue-sky CRISPR dreams than on one practical conversion: turning lonvo-z into a trusted, reimbursed franchise. If that works and ATTR regains credibility, the company can rerate from science project to genetic-medicine operator.

Analysis

Thesis
The non-linear case is that lonvo-z turns Intellia from a collaboration-funded CRISPR story into a real rare-disease franchise, while nex-z recovery and selective licensing let it monetize hard-to-copy editing know-how more than once. If the first commercial in vivo KLKB1 edit builds trusted reimbursement and follow-up rails, 2031 value can rise much faster than current revenue suggests.
Last Economy Alignment
AI helps Intellia compress discovery, manufacturing learning, and clinical coordination, but the real value gates are IP, regulator trust, and verified treatment workflows rather than cheap software.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.7x (from 5 most recent analyses)
Reasoning
The upside case is a business-model change, not just better trial data. If lonvo-z launches on time, Intellia stops looking like a cash-burning research vehicle and starts looking like a focused rare-disease company with one approved franchise, a second meaningful shot in ATTR, and licensing value from its editing stack. That can drive a rerating, but one-time-therapy adoption friction and lingering platform risk keep this below true hypergrowth territory.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The path is sequential and fragile: BLA acceptance must start on time, approval must be clean enough to launch, and launch must translate into reimbursed treatment volume rather than curiosity. The biggest miss scenario is not scientific failure alone; it is approval with slow adoption while nex-z remains too impaired to restore broader platform credibility.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.35
They control something AI cannot cheaply copy: gene-editing IP, human clinical data, and the regulator trust needed to get a permanent treatment approved and paid for. AI can help them move faster, but approval, safety, and reimbursement are still the hard gates that decide whether the flywheel compounds.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$23.94
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case